Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically proven breast cancer~* eligible for six cycles of neoadjuvant or adjuvant chemotherapy~Exclusion Criteria:~* concurrent or prior chemotherapy for breast cancer~* concurrent or prior anti-cancer treatment for breast cancer such as endocrine therapy, immunotherapy, monoclonal antibodies, and/or biological therapy~* concurrent prophylactic antibiotics~* previous therapy with any G-CSF (granulocyte-colony stimulating factor) product~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neulasta® (Type: ACTIVE_COMPARATOR): During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.
- LA-EP2006 (Type: EXPERIMENTAL): During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.

Based on this trial design, predict the completion outcome and termination type (if applicable).